Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CQ72 | ISIN: US1523091007 | Ticker-Symbol: 260
Frankfurt
27.06.25 | 15:29
10,800 Euro
-2,70 % -0,300
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
CENTESSA PHARMACEUTICALS PLC ADR Chart 1 Jahr
5-Tage-Chart
CENTESSA PHARMACEUTICALS PLC ADR 5-Tage-Chart
RealtimeGeldBriefZeit
11,10011,30027.06.
11,10011,40027.06.

Aktuelle News zur CENTESSA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.06.Centessa Pharmaceuticals plc - 8-K, Current Report1
CENTESSA PHARMACEUTICALS Aktie jetzt für 0€ handeln
16.06.Centessa gets clearance to begin trial of ORX1421
16.06.Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year305BOSTON and LONDON, June 16, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration...
► Artikel lesen
29.05.Centessa Pharmaceuticals kündigt Änderungen in der Führungsebene an1
29.05.Centessa Pharmaceuticals plc - 8-K, Current Report2
20.05.Piper Sandler maintains Centessa stock with $38 target1
14.05.Centessa Pharmaceuticals GAAP EPS of -$0.20 beats by $0.15, revenue of $15M1
14.05.Centessa Pharmaceuticals plc - 10-Q, Quarterly Report2
14.05.Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025460Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy...
► Artikel lesen
14.05.Centessa Pharmaceuticals plc - 8-K, Current Report3
08.05.This Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday2
31.03.Piper Sandler sets Centessa stock with $38 target, Overweight rating4
25.03.BMO Capital maintains $35 target on Centessa, cites ORX750 potential2
24.03.Centessa Pharmaceuticals plc - S-8, Securities to be offered to employees in employee benefit plans1
24.03.Centessa Pharmaceuticals plc - 10-K, Annual Report2
24.03.Centessa Pharmaceuticals plc - 8-K, Current Report4
24.03.Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024393Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025 ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type...
► Artikel lesen
06.03.Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting1
05.03.TD Cowen reiterates buy on Centessa stock, sees upside1
21.02.Centessa Pharmaceuticals plc - 8-K, Current Report-
Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1